+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Drug Development Sector Scorecard - Thematic Research

  • PDF Icon


  • 25 Pages
  • January 2021
  • Region: Global
  • GlobalData
  • ID: 5264143
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.


The pharmaceutical industry is under increasing pressures with rising R&D costs, patent expiries, greater competition, and pricing challenges all eroding profit margins. Companies must invest in the right areas of drug development to maximize profitability and minimize risk.

Some of the most profitable or rapidly growing areas include immuno-oncology, regenerative medicine, precision and personalized medicine, biosimilars, genomics, and nanotechnology.
Companies can also forge strategic partnerships in R&D leading to risk diversification, new product development, shortened drug development timelines, and reduced costs. The industry is also investing in new technologies, such as artificial intelligence (AI) to improve drug development.

Our thematic scoring methodology is designed to identify tomorrow’s leaders rather than today’s incumbents, based on their competitive position in the 10 most important themes impacting the landscape.

  • The publisher’s Drug Development Thematic Scorecard report provides a top-down, comprehensive future outlook for key players in the drug development sector over the next two to four years.
  • These themes are Immuno-oncology, Precision and Personalized Medicine, Regenerative Medicine, Rare Disease, Biosimilars, Genomics, Microbiome, Nanotechnology, Strategic Alliances, and Artificial Intelligence.
  • The scorecard includes 55 companies from across the industry, including biopharmaceutical companies, biosimilar and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).
  • The methodology contains detailed information on what data sources were used to generate the thematic scores for each company.

Reasons to Buy
  • Identify the key drug development themes for the next 2-4 years and learn how they will impact the market.
  • Understand which key themes should be addressed to drive share price.
  • Understand which companies are best positioned for success within critical themes and why.
  • Learn which companies have underinvested in key themes and are most vulnerable to disruption.
  • Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
  • Help identify future winners and losers in drug development to inform partnership strategies.

Table of Contents

  • Executive Summary
  • Introduction
  • Pharma Theme Map
  • Drug Development Scorecard
  • Company Screen
  • Thematic Screen
  • Valuation Screen
  • Thematic Research Methodology
  • How Pharma Scores Are Generated
  • Related Reports
  • About the Authors
  • About the Publisher

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Takeda Pharmaceutical Co Ltd
  • Merck & Co Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Pfizer Inc
  • Johnson & Johnson
  • Boehringer Ingelheim
  • Parexel International Corp
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • GlaxoSmithKline Plc
  • Bayer AG
  • Eli Lilly and Co
  • IQVIA Holdings Inc
  • AbbVie Inc
  • Merck KGaA
  • Novo Nordisk AS
  • Catalent Inc
  • Gilead Sciences Inc
  • Thermo Fisher Scientific Inc
  • Astellas
  • Biogen Inc
  • Cipla Ltd
  • Lonza Group Ltd
  • Amgen Inc
  • Daiichi Sankyo Co Ltd
  • Vertex Pharmaceuticals Inc
  • WuXi AppTec Co Ltd
  • Charles River Laboratories International Inc
  • CSL Ltd
  • Reliance Life Sciences Pvt Ltd
  • Sanofi
  • Innovent Biologics Inc
  • Otsuka
  • Teva Pharmaceutical Industries Ltd
  • UCB
  • Dr. Reddy's Laboratories Ltd
  • Regeneron Pharmaceuticals Inc
  • Samsung Bioepis Co Ltd
  • Sun Pharmaceutical Industries Ltd
  • Alexion Pharmaceuticals Inc
  • Biocad
  • Cadila Pharmaceuticals Ltd
  • Celltrion Inc
  • Coherus BioSciences Inc
  • CSPC Pharmaceutical Group Ltd
  • Generium
  • Intas Pharmaceuticals Ltd
  • Lupin Ltd
  • Perrigo Co Plc
  • Pharmaceutical Product Development LLC
  • Seagen Inc
  • Shanghai Henlius Biotech Inc
  • Viatris Inc
  • Zydus Cadila